Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says first patient dosed in its Phase 2 European clinical trial of modified-release hydrocortisone DNL-0200, once referred to as Chronocort. It is being developed to treat adrenal insufficiency. "AI represents a significant market opportunity for the company of approximately USD1.9 billion across Europe and the UK," Diurnal says. Study measuring the treatment against Plenadren, an existing medication.
Current stock price: 56.00 pence
12-month change: down 7.4%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
